Erschienen in:
02.12.2019 | Research Article
Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice
verfasst von:
Yun Zhang, Jing Zhao, Jing Cai, Jia-Cong Ye, Yi-Tai Xiao, Yan Mei, Mu-Sheng Zeng, Chuan-Miao Xie, Yong Jiang, Guo-Kai Feng
Erschienen in:
Molecular Imaging and Biology
|
Ausgabe 4/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Magnetic resonance imaging (MRI) has a high spatial resolution for detecting hepatocellular carcinoma (HCC). Integrin α6 has emerged as a diagnostic and prognostic biomarker of HCC. Here, we developed the MR contrast agent RWY-dL-(Gd-DOTA)4 based on the integrin α6-targeted RWY peptide that we previously identified to detect HCC.
Procedures
Contrast-enhanced MRI was carried out to evaluate the use of RWY-dL-(Gd-DOTA)4 to detect HCC lesions in subcutaneous and diethylnitrosamine (DEN)-induced HCC mouse models.
Results
Enhancement MR signals were observed in HCC-LM3 subcutaneous liver tumors in the first 5 min post-injection of RWY-dL-(Gd-DOTA)4 at a low dose of 0.03 mmol Gd/kg. Moreover, RWY-dL-(Gd-DOTA)4 generated superior contrast enhancement for liver tumors in chemical-induced HCC mice. Importantly, RWY-dL-(Gd-DOTA)4 provided complementary enhancement MR signals to the clinical available hepatobiliary MR contrast agent gadoxetate disodium Gd-EOB-DTPA. Additionally, RWY-dL-(Gd-DOTA)4 showed minimal gadolinium retention in normal tissues and organs at 48 h post-injection.
Conclusion
These findings potentiate the use of RWY-dL-(Gd-DOTA)4 for the MRI of HCC to improve the diagnosis of HCC.